The PrEPWatch Resource Database offers a wide range of material on the status of PrEP as an option for biomedical HIV prevention around the world. Search this database to find step-by-step guidance for rolling out PrEP, summaries of the research to date on safety, efficacy and implementation, tools to assist planning and roll out, country updates on PrEP policy and access, and lessons learned from those efforts.
Showing results 1 - 7 of 7
The Epidemiological Impact and Cost-effectiveness of Key Population-led PrEP Delivery to Prevent HIV among Men who Have Sex with Men in Thailand: A modelling study
This article from The Lancet Southeast Asia discusses the results of a study to determine the epidemiological impact and cost-effectiveness of key population-led PrEP service delivery.
Transgender Women in HPTN 083: An evaluation of safety, efficacy, and gender affirming hormonal therapy interactions with long-acting cabotegravir
This poster from AIDS 2022 presents an analysis of results from the HPTN 083 study, looking at the impact of feminizing gender affirming hormones on cabotegravir (CAB) for PrEP pharmacokinetics.
Asia Region ROP, 2022
The goal of 2022 Regional Operational Plan for the Asia Region is to maintain progress from 2021 in key areas related to health promotion such as refining efforts to eliminate policy barriers, insitutionalizing client- centered services, helping the countries under PEPFAR in the Asia Region achieve 95-95-95, and spotlighting HIV prevention and treatment access for…
Asia Region COP 2021
The goal of 2021 Country Operational Plan for the Asia Region is to maintain progress from 2020 in key areas related to health promotion such as refining efforts to eliminate policy barriers, insitutionalizing client- centered services, helping the countries under PEPFAR in the Asia Region achieve 95-95-95, and spotlighting HIV prevention and treatment access for…
Thailand National Strategy to End AIDS, 2017-30
Thailand's National Strategy to End AIDS has three major targets. To reduce new HIV infections to no more than 1,000 per year, reduce AIDS mortality to no more than 4,000 per year, and to reduce stigma against people living with HIV and nonbinary sexual orientations by 90%. This strategy lays down the basic framework that…
Results from the HPTN 083 Trial
The HIV Prevention Trials Network (HPTN) held a community webinar to discuss the preliminary results of HPTN 083, a global randomized, controlled, double-blinded study that compared the safety and efficacy of long-acting injectable cabotegravir (CAB LA) to daily oral tenofovir/emtricitabine (TDF/FTC) (Truvada) for pre-exposure prophylaxis (PrEP) in transgender women and cisgender men who have sex…
Vaginal Ring Acceptability and Related Preferences among Women in Low- and Middle-income Countries: A systematic review and narrative synthesis
The vaginal ring (VR) is a female-initiated drug-delivery platform used for different indications, including HIV pre-exposure prophylaxis (PrEP). This article outlines a systematic review of VR acceptability, values and preferences among women in low- and middle-income countries (LMIC) to inform further investment and/or guidance on VR use for HIV prevention.